Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | TERT | O14746 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461879 | 0.87 | CYP3A4 (0.65) | NPC1RAB9ATERTCYP3A4L3MBTL1 | |
| SCHEMBL11691760 | 0.82 | CYP3A4 (0.73) | NPC1RAB9ACYP3A4ALDH1A1MEN1 | |
| SCHEMBL9427381 | 0.82 | NPC1 (0.64) | NPC1RAB9ACYP3A4L3MBTL1ALDH1A1 | |
| SCHEMBL10323935 | 0.81 | TERT (0.54) | NPC1RAB9ATERTCYP3A4L3MBTL1 | |
| SCHEMBL9165842 | 0.81 | NPC1 (0.59) | NPC1RAB9ACYP3A4L3MBTL1ALDH1A1 | |
| SCHEMBL2889506 | 0.81 | NPC1 (0.59) | NPC1RAB9ACYP3A4L3MBTL1ALDH1A1 | |
| SCHEMBL6023089 | 0.81 | NPC1 (0.71) | NPC1RAB9ACYP3A4ALDH1A1MEN1 | |
| SCHEMBL11320899 | 0.80 | KMT2A (0.68) | NPC1RAB9AL3MBTL1ALDH1A1MEN1 | |
| SCHEMBL3796789 | 0.78 | NPC1 (0.63) | NPC1RAB9ACYP3A4L3MBTL1ALDH1A1 | |
| SCHEMBL11573244 | 0.78 | ALDH1A1 (0.64) | NPC1RAB9ATERTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | NPC1 1780/4885RAB9A 2086/4885TERT 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.